147 results on '"Horeweg N"'
Search Results
2. Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials
3. Health-related quality of life of breast cancer patients after accelerated partial breast irradiation using intraoperative or external beam radiotherapy technique
4. MO-0050 Feasibility of the determination of the molecular-integrated risk profile in the PORTEC-4a trial
5. OC-0508 Molecular classification of endometrial cancer is predictive of response to adjuvant radiotherapy
6. OC-0602 Development of an evidence-based adjuvant treatment decision support tool for endometrial cancer
7. OC-0601 Early toxicity and quality of life after molecular-based adjuvant treatment in the PORTEC-4a trial
8. PO-1422 Feasibility of bone marrow sparing VMAT and Dixon MRI for the PROTECT study
9. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
10. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program
11. Vaginal brachytherapy management of stage I and II endometrial cancer
12. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment
13. 2022-RA-999-ESGO Clinical relevance of clinicopathological and molecular factors in women with surgically treated stage IV endometrial cancer
14. MO-0802 Five-year oncological outcomes after two different APBI techniques; a prospective cohort study
15. PO-1429 First results of the Leiden-Holland Proton Therapy Center collaboration for uveal melanoma treatment
16. The evolving role of morphology in endometrial cancer diagnostics: From histopathology and molecular testing towards integrative data analysis by deep learning
17. Clinical Outcomes after International Referral of Uveal Melanoma Patients for Proton Therapy
18. PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System
19. 434 Cytoreductive surgery in stage IV endometrial cancer: A retrospective multicentre cohort study
20. 577 Molecular features and prognostic impact of MELF type myometrial invasion in the PORTEC-1/2 cohort of early stage endometrial cancers
21. 397 Molecular profiling of NSMP high-risk endometrial cancers of the PORTEC-3 trial – prognostic refinement and druggable targets
22. 595 Implementation of collaborative translational research (TransPORTEC) findings in an international endometrial cancer clinical trials program (RAINBO)
23. 212 Multiplex qPCR hotspot testing of pathogenic POLE mutations: a rapid, simple and reliable approach for POLE assessment in endometrial cancer
24. 406 Prognostic relevance of the molecular endometrial cancer classification among patients staged by lymphadenectomy and/or without adjuvant treatment
25. 482 Tertiary lymphoid structures as markers of anti-tumor immunity with independent prognostic value in the PORTEC-3 trial of high-risk endometrial cancer
26. Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens
27. PH-0327 Tumour control and visual outcomes after proton therapy for uveal melanoma
28. This week in the journal
29. PO-1587 two years of ocular proton therapy in The Netherlands, clinical results
30. End-of-Life Trajectories of Patients With Hematological Malignancies and Patients With Advanced Solid Tumors Visiting the Emergency Department: The Need for a Proactive Integrated Care Approach
31. Patient Reported Outcomes of Early-Stage Breast Cancer Patients after Different Radiotherapy Regimes
32. PO-0936: Comparison of local recurrence rates after two different APBI techniques, a prospective study
33. 28 Prevalence and prognosis of lynch syndrome and sporadic mismatch repair deficiency in the combined PORTEC-1,-2 and -3 endometrial cancer trials
34. OP60 Evaluation and further development of a dutch question prompt list on palliative care from the perspective of patients and family
35. Prognostic relevance of the molecular classification in high-risk endometrial cancer: analysis of the PORTEC-3 trial
36. PO-0777 Predicting overall survival after radiotherapy for brain metastases in patients with NSCLC
37. OC-0155: The effect of accelerated partial breast irradiation on quality of life
38. PO-0808: Efficacy and toxicity of chemoradiation with brachytherapy for locally advanced cervical cancer
39. OC-0363: Ruthenium-106 brachytherapy for iris and choroidal body melanomas
40. An Official American Thoracic Society Research Statement: A Research Framework for Pulmonary Nodule Evaluation and Management
41. LUNG CANCER PROBABILITY IN SUBJECTS WITH CT-DETECTED PULMONARY NODULES
42. Reply: Stage Distribution of Lung Cancers Detected by Computed Tomography Screening in the NELSON Trial
43. PO-0763: Ruthenium-106 brachytherapy for choroidal melanoma: high efficacy with improved visual outcome
44. THE ROLE OF A CONVENTIONAL BRONCHOSCOPY IN THE WORK-UP OF SUSPICIOUS CT SCREEN DETECTED PULMONARY NODULES
45. COMPLICATIONS FOLLOWING LUNG SURGERY IN THE NELSON LUNG CANCER SCREENING TRIAL: A COMPARISON WITH THE LITERATURE
46. Agreement of diameter- and volume-based pulmonary nodule management in CT lung cancer screening
47. 15O VOLUMETRIC COMPUTER TOMOGRAPHY SCREENING FOR LUNG CANCER: THREE ROUNDS OF THE NELSON TRIAL
48. Blinded and uniform cause of death verification in a lung cancer CT screening trial
49. Complications following lung surgery in the Dutch-Belgian randomized lung cancer screening trial
50. Ruthenium-106 brachytherapy for uveal melanoma without transpupillary thermotherapy: similar efficacy with improved visual outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.